Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Continuous Manufacturing Back In Second Act

Executive Summary

House tries again to promote advanced technology for the return of pharmaceutical manufacturing to the US in post-COVID-19 era.

You may also be interested in...



Can 'Buy American’ Executive Order Shake Up ‘Dickensian’ Manufacturing Dynamics?

Order sets a path for federal government to use its power as a purchaser of pharmaceuticals to nurture a high-tech domestic pharma manufacturing sector that would increase resilience against threats that could isolate the US from countries like China that are important nodes in the global manufacturing supply chain.

Can 'Buy American’ Executive Order Shake Up ‘Dickensian’ Manufacturing Dynamics?

The Trump administration’s move to strengthen domestic manufacture of essential medicines raises a lot of questions – and industry’s ire.

US FDA Sees Slow But Steady Progress In Adoption Of Continuous Manufacturing

The COVID-19 pandemic has prompted the ICH to delay by six months its efforts to develop Q13 guideline on continuous manufacturing, now not expected until May 2022.

Related Content

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel